November 1, 2009
By:Wayne Kuznar
A study shows that most patients with nocturia have nocturnal polyuria, which is consistent with other studies showing that overproduction of urine at night is a major contributory factor to nocturia in about 80% of patients.
 |
November 1, 2009
By:Shlomo Raz, MD, Ja-Hong Kim, MD
Drs. Shlomo Raz and Ja-Hong Kim discuss recent advances in the treatment of stress incontinence.
|
September 1, 2009
By:Scott Tennant
BPH and lower urinary tract symptoms are very common, increase as a function of age, and are often managed through watchful waiting.
|
September 1, 2009
By:Scott Tennant
Light-activated drug therapy for BPH has been shown to be safe and painless in a phase I/II trial.
|
June 1, 2009
By:Cheryl Guttman
Findings from a multicenter, randomized, double-blind, placebo-controlled study are consistent with previously reported data showing that tadalafil (Cialis) improves lower urinary tract symptoms associated with BPH.
|
May 1, 2009
By:Zvi Gregory Wirschubsky, MD, PhD
Anticholinergic drugs also are effective and safe in men who have lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) secondary to BPH, a new study suggests.
|
May 1, 2009
By:Zvi Gregory Wirschubsky, MD, PhD
A new alpha-blocker for the treatment of BPH shows positive results with minimal cardiovascular side effects, according to a presentation made during the European Association of Urology annual congress
|
May 1, 2009
By:Michael P. O'Leary, MD
While medical therapy remains the mainstay of treatment for most men with symptomatic BPH and surgery is required for severe, progressive disease, injectables may offer a number of theoretical advantages.
|
May 1, 2009
By:Cheryl Guttman
Transperineal intraprostatic injection of a PSA-activated protoxin (PRX302) provides lasting symptomatic relief and improvement in quality of life for men with BPH, according to 1-year follow-up data from a phase I study.
|
| 
Practice Tools
Brings you the latest news and information twice each month.